Nicotinic acid bufus - instructions for use, dose, side effects, contraindications

Nicotinic acid is a specific anti-pelagic agent. Has a pronounced short vasodilating effect, improves carbohydrate and nitrogen metabolism, has lipid-lowering activity, reduces the content of total cholesterol, low-density lipoproteins, improves microcirculation.

In organism a nicotinic acid turns into nicotinamide, which binds to coenzymes I and II of codegirogen I and II (NAD and NADO), which carry hydrogen, participates in the metabolism of fats, proteins, amino acids, purines, tissue respiration, glycogenolysis, and synthetic processes. Replenishes vitamin deficiency PP (vitamin A Ve), is a specific antipelagic agent (vitamin avitaminosis PP).

Normalizes the concentration of blood lipoproteins.

Has vasodilating effect at the level of small vessels (incl.brain), improves microcirculation, has a weak anticoagulant effect (increases the fibrinolytic activity of the blood).

Pharmacokinetics:

When parenteral introduction, quickly distributed in the tissues of the body. In the body it is transformed into nicotinamide. It accumulates mainly in the liver, as well as in adipose tissue and in the kidneys. In the liver a nicotinic acid is converted into an amine that is embedded in nicotinamide adenine dinucleotide (NAD), which is a prosthetic group of enzymes that carry hydrogen and carry out oxidation-reduction processes.

Metabolised in the liver. The main metabolites - N-methyl-2-pyridone-3-carboxamide and N-methyl-2-pyridone-5-carboxamide do not have pharmacological activity.

It can be synthesized in the intestine by a bacterial flora from the tryptophan that came with food (1 mg of nicotinic acid is formed from 60 mg of tryptophan) with the participation of pyridoxine (vitamin B6) and riboflavin (vitamin B12). The elimination half-life is 45 minutes.

It is excreted by the kidneys in the form of metabolites, when taking high doses - mostly unchanged. Kidney clearance depends on the level of nicotinic acid in the blood plasma and can decrease with a high concentration of it in the plasma.

Indications:Hypovitaminosis PP, avitaminosis PP (pellagra).Ischemic disorders of cerebral circulation, obliterating diseases of the vessels of the extremities (obliterating endarteritis, Raynaud's disease), spasm of the vessels of the extremities, bile and urinary tract, neuritis of the facial nerve. Diabetes mellitus, including its complications (diabetic polyneuropathy, microangiopathy, Hartnup disease (hereditary disease, accompanied by a violation of the assimilation of certain amino acids, including tryptophan).

Contraindications:

Hypersensitivity, severe arterial hypertension, atherosclerosis, gout, hyperuricemia, children's age. Pregnancy, lactation.

Carefully:Hemorrhagia, glaucoma, hepatic insufficiency, arterial hypotension, hyperacid gastritis, peptic ulcer and duodenal ulcer (at the stage of exacerbation).

Pregnancy and lactation:Taking into account the injection route of the drug, side effects, there is no need for use during pregnancy.

Dosing and Administration:

When pellagra is administered to adults parenterally (subcutaneously, intramuscularly - but, intravenously (slowly) - 10 mg (1% solution of 1 ml) 2-3 times a day, for 10-15 days.With ischemic stroke, 10 mg of solution is slowly injected intravenously.

At other indications - on 10 mg 1-2-aza in day, within 10-15 days. Higher doses for adults: one-time - 0.1 g, daily - 0.3 g.

Disease Hartnup 40-200 mg per day.

Side effects:

Allergic reactions (skin rash, itchy skin, breathy breath, hives).

After intravenous rapid administration: orthostatic hypotension, collapse.

Hyperemia of the skin of the face and upper body, paresthesia, dizziness, "tides" of blood to the skin of the face, headache, dizziness. Local reactions: soreness in places of subcutaneous and intramuscular injection.

Overdose:High doses of nicotinic acid can cause a temporary rush of blood to the head and upper body, itching, and gastrointestinal upsets. Treatment: symptomatic.

Interaction:

When combined with the drugs, sulfonylureas can increase blood glucose levels.

Care should be taken when combining with antihypertensive drugs, anticoagulants and ascorbic acid.

Reduces the toxicity of neomycin and prevents the induced decrease in the concentration of high-density cholesterol and lipoproteins.

Special instructions:

During the treatment it is necessary to monitor the function of the liver.

To prevent complications from the liver it is recommended to include in the diet products rich in methionine (cottage cheese), or use methionine, lipoic acid, and other lipotropic lipids.

Effect on the ability to drive transp. cf. and fur:

Form release / dosage:

Solution for injection 10 mg / ml.

1 ml per ampoule polymeric polyethylenehigh-pressure or polyethylene low pressure, or from polyethylene for medical purposes, or from polyethylene or polypropylene for infusion racescreams and injections.

For polymer ampoules paste thiskletki from paper label, writing or

The text of the label is applied directly to the ampoule polymeric drop-jet methodprinting.

10, 100 ampoules of polymer with instructionsher use on the package in a pack of cardboard.

Packaging:ampoules polypropylene (10) - packs cardboard
ampoules polypropylene (100) - packs cardboard
ampoules polyethylene (10) - packs cardboard
ampoules polyethylene (100) - packs cardboard

Storage conditions:

In the dark place at a temperaturenot more than 25 ° C.

Keep out of the reach of children.

Shelf life:

5 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-001476/09

Date of registration:03.03.2009

The owner of the registration certificate:UPDATE OF PFC, CJSC UPDATE OF PFC, CJSC Russia

Manufacturer: & nbsp

UPDATE, PFC CJSC Russia

Information update date: & nbsp13.08.2015

Illustrated instructions

Instructions

Nicotinic acid bufus (Nicotinic acid bufus)